Skip to main content
Andrew Intlekofer, MD, Oncology, New York, NY

AndrewMichaelIntlekoferMDPhD

Oncology • New York, NY

Assistant Member, Human Oncology & Pathogenesis Program; Assistant Attending, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center

Request Appointment

Overview of Dr. Intlekofer

Dr. Andrew Intlekofer is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 8 years. He is one of 494 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 50 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2015
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2009 - 2011
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2009

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2018 - 2025
  • NY State Medical License
    NY State Medical License 2011 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface Mutations  
    Martin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature

Abstracts/Posters

  • Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
    Andrew M. Intlekofer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
    Andrew M. Intlekofer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Dr. Andrew Intlekofer, Dr. Andrew Intlekofer, MD, Dr. A Intlekofer, Dr. Andrew Michael Intlekofer